As Biotechnology businesses, REGENXBIO Inc. (NASDAQ:RGNX) and Geron Corporation (NASDAQ:GERN), are affected by contrast. This especially applies to their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
Table 1 shows top-line revenue, earnings per share and valuation of the two companies.
Table 2 shows the net margins, return on assets and return on equity of the two firms.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
REGENXBIO Inc. has a 0.46 beta, while its volatility is 54.00%, thus making it less volatile than Standard and Poor’s 500. Competitively, Geron Corporation’s beta is 2.96 which is 196.00% more volatile than Standard and Poor’s 500.
20.2 and 20.2 are the respective Current Ratio and a Quick Ratio of REGENXBIO Inc. Its rival Geron Corporation’s Current and Quick Ratios are 37.8 and 37.8 respectively. Geron Corporation has a better chance of clearing its pay short and long-term debts than REGENXBIO Inc.
The Recommendations and Ratings for REGENXBIO Inc. and Geron Corporation are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
On the other hand, Geron Corporation’s potential upside is 100.57% and its average price target is $3.5.
Insider and Institutional Ownership
REGENXBIO Inc. and Geron Corporation has shares held by institutional investors as follows: 85.5% and 34.1%. About 1.5% of REGENXBIO Inc.’s share are held by insiders. Comparatively, 0.48% are Geron Corporation’s share held by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
For the past year REGENXBIO Inc. has weaker performance than Geron Corporation
Geron Corporation beats REGENXBIO Inc. on 6 of the 11 factors.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The companyÂ’s lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV vectors to various other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.